| Quarterly Financials | Jun 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
Revenue  | 540 | 645 | 636 | 647 | 687 | 699 | 699 | 708 | 758 | 781 | 783 |
| Expenses | 413 | 535 | 511 | 515 | 525 | 534 | 548 | 561 | 589 | 608 | 606 |
| EBITDA | 127 | 111 | 125 | 133 | 162 | 164 | 151 | 148 | 170 | 173 | 177 |
| Operating Profit % | 21 % | 15 % | 16 % | 19 % | 22 % | 21 % | 19 % | 18 % | 18 % | 20 % | 20 % |
| Depreciation | 10 | 20 | 20 | 20 | 18 | 19 | 20 | 19 | 20 | 21 | 22 |
| Interest | 2 | 12 | 13 | 12 | 12 | 12 | 12 | 4 | 3 | 3 | 4 |
| Profit Before Tax | 115 | 79 | 93 | 101 | 132 | 134 | 120 | 124 | 146 | 149 | 152 |
| Tax | 29 | 30 | 24 | 26 | 34 | 39 | 32 | 32 | 37 | 32 | 36 |
| Net Profit | 86 | 49 | 68 | 75 | 99 | 95 | 88 | 92 | 110 | 118 | 116 |
| EPS in ₹ | 3.88 | 2.20 | 3.09 | 3.38 | 4.45 | 4.27 | 3.79 | 3.84 | 4.59 | 4.91 | 4.86 |
Indegene
Indegene
563.80
-9.20
(-1.61%)
Market Cap
13,539.07 Cr
EPS
17.15
PE Ratio
31.56
Dividend Yield
0.35 %
Industry
Healthcare52 Week High
736.30
52 Week Low
499.00
PB Ratio
5.25
Debt to Equity
0.15
Sector
Healthcare Technology
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from6 analysts
Company News
View All News
Indegene Limited hosted its 7th annual Digital Summit 2025 in Philadelphia, bringing together senior life sciences executives to explore AI transformation in commercialization. The invite-only event featured the theme 'From Chaos to Clarity - and Better Decisions' with focus on Generative AI applications. The summit included discussions on data unification, agent-augmented workforce, GenAI in commercial operations, and evolving pharma regulations. The event also presented the Vital Awards recognizing industry leaders across four categories: Patient Impact, Community Impact, Organizational Impact, and Market Impact. Award recipients included executives from AstraZeneca, Merck, and Sanofi. The jury comprised senior leaders from companies including Gilead Sciences, Merck, and academic institutions. Manish Gupta, Chairman and CEO of Indegene, congratulated the honorees for their innovation and impact in helping the industry become future-ready.
Indegene Limited announced a strategic partnership with Datavant to improve patient recruitment for clinical trials, particularly focusing on rare disease and complex studies. The collaboration integrates Datavant's data enrichment capabilities into Indegene's NEXT Patient Recruitment platform. Datavant operates a health data retrieval network spanning over 80,000 hospitals and clinics, processing more than 100 million patient records annually. The partnership aims to enable faster trial enrollment, reduce screen failures, and streamline identification of suitable participants based on specific health data criteria. This allows more eligible participants to connect with trials for their specific health conditions and helps biopharmaceutical companies accelerate enrollment timelines and improve screen-to-randomization ratios.
Indegene Limited, a digital-first life sciences commercialization company, has opened a new center in Pune to expand its presence in India. The company aims to leverage Pune's skilled technology, management, and medical talent to enhance its ability to help clients accelerate innovation and scale global operations. Indegene serves the world's top 20 biopharma companies, emerging biotech firms, and medical device companies. The company has approximately 5,000 employees worldwide across 9 operations hubs and 20 offices in North America, Europe, and Asia.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
620.00 | #1 24,982.24 | 48.83 | #1 3,714.20 | 3.77 | #1 496 | 14.53 | 32.36 | |
563.80 | #2 13,539.07 | #1 31.56 | #2 2,946.50 | #4 10.53 | #2 407 | #4 32.73 | 53.88 | |
201.23 | 4,577.46 | - | 17.60 | -46.34 | -161 | -83.93 | 38.22 | |
703.35 | 3,132.78 | 50.89 | 322.30 | 0.22 | 41 | #1 112.87 | 47.98 | |
84.42 | 198.77 | - | 806.50 | 4.78 | -56 | 34.67 | 55.35 | |
11.49 | 169.98 | 60.67 | 10.20 | #1 126.67 | 1 | 76.32 | 48.06 | |
33.50 | 53.05 | 493.63 | 47.50 | 17.87 | 0 | -420.00 | 28.31 | |
17.25 | 26.30 | 33.09 | 84.00 | 5.00 | 2 | -92.68 | 47.31 | |
24.26 | 15.30 | - | 1.96 | 40.00 | -13 | -566.67 | 47.96 |
Forecast
Actual
Growth Rate
Revenue Growth
10.53 %
Net Income Growth
20.79 %
Cash Flow Change
-12.96 %
ROE
-34.00 %
ROCE
-22.58 %
EBITDA Margin (Avg.)
-0.23 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 329 | 600 | 596 | 1,354 | 2,204 | 2,546 | 3,326 |
| Fixed Assets | 104 | 119 | 86 | 138 | 664 | 646 | 678 |
| Current Assets | 185 | 418 | 459 | 1,130 | 1,449 | 1,791 | 2,530 |
| Capital Work in Progress | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
| Investments | 0 | 13 | 0 | 120 | 614 | 797 | 1,290 |
| Other Assets | 225 | 468 | 510 | 1,096 | 926 | 1,103 | 1,355 |
| Total Liabilities | 329 | 600 | 596 | 1,354 | 2,204 | 2,546 | 3,326 |
| Current Liabilities | 158 | 247 | 199 | 440 | 489 | 611 | 565 |
| Non Current Liabilities | 18 | 369 | 64 | 149 | 651 | 506 | 146 |
| Total Equity | 152 | -16 | 333 | 764 | 1,064 | 1,429 | 2,616 |
| Reserve & Surplus | 73 | -105 | 324 | 764 | 1,020 | 1,385 | 2,567 |
| Share Capital | 79 | 0 | 0 | 0 | 44 | 44 | 48 |
Cash Flow
| Cash Flow | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 25 | 143 | -41 | 373 | -433 | 115 | 52 |
| Investing Activities | -18 | -16 | -81 | -158 | -896 | -327 | -677 |
| Operating Activities | 65 | 22 | 172 | 297 | 130 | 508 | 442 |
| Financing Activities | -21 | 136 | -132 | 234 | 333 | -66 | 288 |
Share Holding
| % Holding | Dec 2022 | Mar 2024 | Apr 2024 | May 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
| Promoter | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| FIIs | 0.00 % | 3.56 % | 0.00 % | 0.00 % | 3.79 % | 4.82 % | 5.03 % | 5.24 % | 10.05 % |
| DIIs | 0.00 % | 5.33 % | 0.00 % | 0.00 % | 3.84 % | 3.17 % | 3.98 % | 4.96 % | 7.20 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 0.00 % | 11.38 % | 0.00 % | 0.00 % | 24.67 % | 24.32 % | 26.41 % | 11.34 % | 13.51 % |
| Others | 100.00 % | 79.73 % | 100.00 % | 100.00 % | 67.70 % | 67.69 % | 64.58 % | 78.45 % | 69.24 % |
| No of Share Holders | 44 | 4,43,785 | 82 | 82 | 2,03,599 | 1,51,440 | 1,53,789 | 1,44,708 | 1,51,997 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.35 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 17 Nov 2022 |  Change Of Name | NA | 17 Nov 2022 | 0.00 | 0.00 |
| 06 Sept 2024 |  Annual General Meeting | NA | 06 Sept 2024 | 554.85 | 608.85 |
| 28 Oct 2024 |  Quarterly Result Announcement | NA | 28 Oct 2024 | 653.25 | 675.45 |
| 30 Jan 2025 | Quarterly Result Announcement | NA | 30 Jan 2025 | 663.05 | 622.10 |
| 28 Apr 2025 | Quarterly Result Announcement | NA | 28 Apr 2025 | 570.25 | 567.40 |
| 13 Jun 2025 |  Dividend | ₹ 2.00 /share | 13 Jun 2025 | 567.40 | 598.55 |
| 26 Jun 2025 | Annual General Meeting | NA | 26 Jun 2025 | 609.15 | 580.55 |
| 31 Jul 2025 | Quarterly Result Announcement | NA | 31 Jul 2025 | 558.95 | 546.55 |
Announcements
Closure of Trading Window
3 days ago
3 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release5 days ago
5 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release10 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 05, 2025
Sep 05, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 01, 2025
Sep 01, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSAug 21, 2025
Aug 21, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 19, 2025
Aug 19, 2025 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportAug 13, 2025
Aug 13, 2025Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotAug 13, 2025
Aug 13, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 06, 2025
Aug 06, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 02, 2025
Aug 02, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 01, 2025
Aug 01, 2025Announcement under Regulation 30 (LODR)-Investor PresentationJul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-Monitoring Agency ReportJul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJul 31, 2025
Jul 31, 2025Intimation Of Outcome Of Board MeetingJul 31, 2025
Jul 31, 2025Board Meeting Outcome for Intimation Of Outcome Of Board MeetingJul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 30, 2025
Jul 30, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 30, 2025
Jul 30, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 24, 2025
Jul 24, 2025Board Meeting Intimation for Consideration Of The Unaudited Standalone And Consolidated Financial Results For The Quarter Ended June 30 2025 Along With The Limited Review Report Of The Auditors Thereon.Jul 24, 2025
Jul 24, 2025Announcement under Regulation 30 (LODR)-AcquisitionJul 23, 2025
Jul 23, 2025Announcement under Regulation 30 (LODR)-Resignation of DirectorJul 22, 2025
Jul 22, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceJul 15, 2025
Jul 15, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 12, 2025
Jul 12, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 11, 2025
Jul 11, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 11, 2025
Jul 11, 2025Shareholder Meeting / Postal Ballot-Notice of Postal BallotJul 11, 2025
Jul 11, 2025Disclosure Under Regulation 30 Of SEBI LODR Regulations 2015Jul 10, 2025
Jul 10, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 03, 2025
Jul 03, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 30, 2025
Jun 30, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportJun 27, 2025
Jun 27, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMJun 27, 2025
Jun 27, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMJun 27, 2025
Jun 27, 2025Closure of Trading WindowJun 27, 2025
Jun 27, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMJun 26, 2025
Jun 26, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 16, 2025
Jun 16, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 09, 2025
Jun 09, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 06, 2025
Jun 06, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 05, 2025
Jun 05, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 03, 2025
Jun 03, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 31, 2025
May 31, 2025Letter To Non-Email Members Providing Web Link Of Annual Report For FY 2024-25.May 30, 2025
May 30, 2025Business Responsibility and Sustainability Reporting (BRSR)May 30, 2025
May 30, 2025Annual Report For FY 2024-25 And Notice Of The 27Th Annual General MeetingMay 30, 2025
May 30, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 29, 2025
May 29, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateMay 27, 2025
May 27, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMay 27, 2025
May 27, 2025Record Date For The Purpose Of DividendMay 27, 2025
May 27, 2025Technical Indicators
RSI(14)
Neutral 52.02
ATR(14)
Volatile 13.65
STOCH(9,6)
Neutral 38.83
STOCH RSI(14)
Neutral 42.08
MACD(12,26)
Bullish 0.29
ADX(14)
Weak Trend 14.25
UO(9)
Bearish 54.42
ROC(12)
Uptrend And Accelerating 0.74
WillR(14)
Neutral -52.48
Mutual Fund Holdings
Invesco India Smallcap Fund Direct - Growth 
Edelweiss Recently Listed IPO Fund Direct-Growth 
Baroda BNP Paribas Flexi Cap Fund Direct - Growth 
Sundaram Mid Cap Fund Direct-Growth 
Helios Mid Cap Fund Direct-Growth 
Shriram Flexi Cap Fund Direct - Growth 
Motilal Oswal Quant Fund Direct-Growth 
JioBlackRock Nifty Smallcap 250 Index Fund Direct - Growth 
Nippon India Nifty Smallcap 250 Index Fund Direct - Growth 
SBI Nifty Smallcap 250 Index Fund Direct - Growth 
HDFC Nifty Smallcap 250 Index Fund Direct-Growth 
ICICI Prudential Nifty Smallcap 250 Index Fund Direct - Growth 
Bandhan Nifty Smallcap 250 Index Fund Direct-Growth 
Kotak Nifty Smallcap 250 Index Fund Direct-Growth 
Groww Nifty Smallcap 250 Index Fund Direct - Growth 
Axis Nifty 500 Index Fund Direct-Growth About Indegene
Indegene Limited is a global provider of digital-led commercialization services for the life sciences industry. The company offers solutions in analytics, technology, and commercial, medical, regulatory, and safety services to biopharmaceutical, emerging biotech, and medical devices companies. Indegene operates through four main segments: Enterprise Commercial Solutions, Omnichannel Activation, Enterprise Medical Solutions, and Others. These segments assist with digital marketing operations, last-mile promotion optimization, regulatory and medical operations consolidation, and clinical solutions and consultancy services. The company has made several acquisitions to expand its capabilities, including Encima Group, DT Associates, Cult Health, and Trilogy Writing & Consulting GmbH. In 2023, Indegene launched Invisage, an AI-enabled hybrid omnichannel sales and marketing platform. The company completed a public issue in May 2024, raising funds through a fresh issue and offer for sale.
Listing Date
13 May, 2024(1 Years,
17 days)
Website
Chairperson NameManish Gupta
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
